Friday, 16 October 2026European Markets

PEXIP HOLDING Stock Went Up By Over 25% In The Last 10 Sessions

Loading stream...

(VIANEWS) - Shares of PEXIP HOLDING (Oslo Børs All-share Index_GI: PEXIP.OL) rose by a staggering 25.3% in 10 sessions from $12.65 to $15.85 at 13:50 EST on Monday, following the last session's upward trend. Oslo Børs All-share Index_GI is dropping 0.89% to $1,365.78, after successive sessions in a row of losses.

PEXIP HOLDING's last close was $14.26, 66.93% under its 52-week high of $43.12.

About PEXIP HOLDING

Pexip Holding ASA provides a video-first meeting platform worldwide. The company offers self-hosted software application and as-a-service deployment options for enterprise video conferencing, built on its proprietary Infinity technology. Its interoperability solutions are integrated into Microsoft Teams, Skype for Business, and Google Hangouts Gateway interop, a video system device registration and a meeting and calling service. The company serves government, healthcare, education, finance, legal, and retail industries. Pexip Holding ASA was founded in 2011 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, PEXIP HOLDING has a trailing twelve months EPS of $-0.95.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -12.89%.

Sales Growth

PEXIP HOLDING's sales growth for the current quarter is 12.8%.

Volume

Today's last reported volume for PEXIP HOLDING is 1108117 which is 141.13% above its average volume of 459548.

Yearly Top and Bottom Value

PEXIP HOLDING's stock is valued at $15.85 at 13:50 EST, way under its 52-week high of $43.12 and way above its 52-week low of $7.98.

More news about PEXIP HOLDING (PEXIP.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com